Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Lymphoma 68Lymphoma, Non-Hodgkin 53Lymphoma, Large B-Cell, Diffuse 47Hodgkin Disease 42Precursor Cell Lymphoblastic Leukemia-Lymphoma 41Leukemia, Myeloid, Acute 41Small Cell Lung Carcinoma 37Leukemia 37Burkitt Lymphoma 32Lymphoma, Mantle-Cell 29Lymphoma, Follicular 28Lung Neoplasms 20Carcinoma, Non-Small-Cell Lung 20Multiple Myeloma 19Congenital Abnormalities 18Lymphoma, Large-Cell, Immunoblastic 17Lymphoma, Large-Cell, Anaplastic 17Recurrence 15Lymphoma, B-Cell, Marginal Zone 15Lymphoma, B-Cell 15Leukemia, Lymphocytic, Chronic, B-Cell 15Neuroblastoma 13Neoplasms 13Myelodysplastic Syndromes 11Waldenstrom Macroglobulinemia 10Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 10Lymphoma, T-Cell 10Immunoblastic Lymphadenopathy 10Sarcoma 9Myeloproliferative Disorders 9

Interventions

venetoclax 1magrolimab 1cc-486 1Mitoxantrone 1Etoposide 1Cytarabine 1Azacitidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Myeloid Malignancies × Etoposide × Clear all
NCT04778410 2025-03-20

Study of Magrolimab Combinations in Participants With Myeloid Malignancies

Gilead Sciences

Phase 2 Terminated
54 enrolled 26 charts

Myeloid Malignancies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡